MacroGenics: Q3 Earnings Snapshot
MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress
Macrogenics Q3 EPS $(0.34) Misses $(0.12) Estimate, Sales $18.667M Miss $43.748M Estimate
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors
MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer
MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
MacroGenics Announces Phase 1 MGC026 Delivers 27% Response Rate In SCCHN, Showing Durable Tumor Activity And Advancing Toward Front-Line Pembrolizumab Combination Trial
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors
MacroGenics Doses First Patient In Phase 1 Study Of MGC030, Antibody-Drug Conjugate Directed Against Undisclosed Target, In Patients With Advanced Solid Tumors
MacroGenics (NASDAQ:MGNX): A Minervini Trend Template High-Growth Momentum Case Study
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
UPDATE: Macrogenics Q2 Adj. EPS $(0.27) Misses $(0.13) Estimate, Sales $32.832M Miss $67.456M Estimate
MacroGenics Announces Gilead Sciences Exercises Option For Exclusive License To Preclinical Bispecific Program Under 2022 Collaboration, Triggering $10M Payment
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
MacroGenics Plans To Present Dose Escalation And Preliminary Tumor-Specific Cohort Results At The European Society For Medical Oncology Congress, October 23-27
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.